Novavax shares are up on Monday following a licensing agreement with Pfizer for the use of its Matrix-M adjuvant.
Zacks Investment Research on MSN
Novavax, Inc. (NVAX) is a trending stock: Facts to know before betting on it
Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...
Get all latest & breaking news on Serum Institute Of India. Watch videos, top stories and articles on Serum Institute Of ...
ETHealthworld.com brings latest takeda pharmaceutical news, views and updates from all top sources for the Indian Health industry.
Get all latest & breaking news on Adar Poonawala. Watch videos, top stories and articles on Adar Poonawala at moneycontrol.com.
GSK is set to buy Rapt Therapeutics in a $2.2 billion deal. AstraZeneca agreed to a $630 million pact to secure remaining rights to armored CAR-T from AbelZeta. Bristol Myers Squibb signed a deal with ...
Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to ...
In the latest close session, Novavax (NVAX) was down 1.97% at $9.71. This change lagged the S&P 500's 0.55% gain on the day.
GoodRx reports on tracking prescription fills for flu and COVID-19 treatments, revealing seasonal trends and insurance coverage disparities.
In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging ...
The unprecedented changes have led to diminished vaccine usage, and created a drag that will likely dent revenues.
Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innov ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results